Abstract LB-068: From intracellular antibody fragments to small molecule inhibitors of mutant KRAS

Abstract LB-068: From intracellular antibody fragments to small molecule inhibitors of mutant KRAS

Detalles Bibliográficos
Main Authors:	Quevedo, C, Cruz, A, Tulmin, H, Bataille, C, Tanaka, T, Petch, D, Russell, A, Phillips, S, Rabbitts, T
Formato:	Journal article
Idioma:	English
Publicado:	American Association for Cancer Research 2017

Títulos similares

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
por: Quevedo, C, et al.
Publicado: (2018)

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
por: Camilo E. Quevedo, et al.
Publicado: (2018-08-01)

BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
por: Bery, N, et al.
Publicado: (2018)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Nicolas Bery, et al.
Publicado: (2020-06-01)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Ke Xu, et al.
Publicado: (2019-04-01)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
por: Ke Xu, et al.
Publicado: (2020-05-01)

Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture.
por: Tanaka, T, et al.
Publicado: (2010)

Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds.
por: Tanaka, T, et al.
Publicado: (2008)

BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
por: Nicolas Bery, et al.
Publicado: (2018-07-01)

Correction: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
por: Nicolas Bery, et al.
Publicado: (2018-08-01)

P068: Withdrawn
Publicado: (2024-01-01)

Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies.
por: Tanaka, T, et al.
Publicado: (2003)

Abstract 068: Basilar artery bifurcation anatomy as a determinant of recanalization and stroke outcome
por: Mohammad Hossein Abbasi, et al.
Publicado: (2023-11-01)

Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules.
por: Lobato, M, et al.
Publicado: (2004)

The selection of single-domain antibody fragments (iDAbs) by intracellular antibody capture in yeast
por: Rabbitts, T, et al.
Publicado: (2018)

A pan-KRAS degrader for the treatment of KRAS-mutant cancers
por: Jie Yang, et al.
Publicado: (2024-06-01)

Isolation of antigen-specific intracellular antibody fragments as single chain Fv for use in mammalian cells.
por: Tse, E, et al.
Publicado: (2002)

Intracellular antibody capture (IAC) methods for single domain antibodies.
por: Tanaka, T, et al.
Publicado: (2012)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Xiufeng Pang, et al.
Publicado: (2016-10-01)

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
por: Satoru Miyazaki, et al.
Publicado: (2025-02-01)

A 0.68V 0.68mW 2.4GHz PLL for ultra-low power RF systems
por: Paidimarri, Arun, et al.
Publicado: (2015)

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
por: Helen Adderley, et al.
Publicado: (2019-03-01)

Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation.
por: Tanaka, T, et al.
Publicado: (2003)

Role of silent mutations in KRAS-mutant tumors
por: Jun Lu, et al.
Publicado: (2025-02-01)

Small molecular inhibitors for KRAS-mutant cancers
por: Xuan Wu, et al.
Publicado: (2023-08-01)

In silico analysis of wild-type and mutant KRAS
por: Frengki Frengki, et al.
Publicado: (2019-05-01)

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Jieqiong Wang, et al.
Publicado: (2016-05-01)

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
por: Kohei Maruyama, et al.
Publicado: (2025-01-01)

A Cell-based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-drug Proteins
por: Nicolas Bery, et al.
Publicado: (2022-02-01)

TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation
por: Ying Shen, et al.
Publicado: (2020-11-01)

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu X, et al.
Publicado: (2019-08-01)

LSC Abstract – Host-environmental IL-1b drives mutant KRAS-IKKa addiction in malignant pleural effusion
por: Marazioti, A, et al.
Publicado: (2016)

5.068 Physical Methods in Inorganic Chemistry, Spring 2005
por: Mueller, Peter
Publicado: (2005)

P.068 ENDOTHELIAL FUNCTION AND ARTERIAL STIFFNESS IN PATIENTS WITH SCLERODERMIA
por: M. Bernardini*, et al.
Publicado: (2007-06-01)

Mutant KRAS promotes malignant pleural effusion formation
por: Theodora Agalioti, et al.
Publicado: (2017-05-01)

Intracellular antibodies and cancer: new technologies offer therapeutic opportunities.
por: Pérez-Martínez, D, et al.
Publicado: (2010)

Exploring KRas Protein Dynamics: An Integrated Molecular Dynamics Analysis of KRas Wild and Mutant Variants
por: Showkat Ahmad Mir, et al.
Publicado: (2024-07-01)

Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domain.
por: Tanaka, T, et al.
Publicado: (2011)

Mutant KRAS promotes malignant pleural effusion formation
por: Αgalioti, T, et al.
Publicado: (2017)

Intracellular immunization against HIV infection with an intracellular antibody that mimics HIV integrase binding to the cellular LEDGF protein
por: Bao, L, et al.
Publicado: (2017)